In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting ...

RiDYMO® has been successfully employed in various drug discovery programs, including the development of small molecule ...

Glaucoma is a progressive eye disorder characterized by fluid buildup inside the eye, causing ocular hypertension. By 2040, ...

Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics ...

Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and ...

Stoke Therapeutics (STOK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein ...

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

By combining diverse datasets and powerful analytical and modeling tools, drug developers are finding more potential ...

The starting point for all structure-based design work, whether ligand or protein based, is the choice of a suitable target. Antimicrobial-drug targets should be essential, have a unique function ...